Comparison of Silodosin and Dapoxetine in “on-demand” treatment of Premature ejaculation:A randomized controlled study
European Journal of Molecular & Clinical Medicine,
2022, Volume 9, Issue 3, Pages 2819-2823
AbstractAim: To compare Silodosin and Dapoxetine in the “on-demand” treatment of premature ejaculation.
Material and method: The study was conducted in the department of urology and renal transplant S.M.S. Medical College Jaipur from 1st January 2018 to 31st December 2018. We enrolled 90 self-reported casesof PME and excluded the patients below 18 years and above 50 years; patients suffering from orthostatic hypotension, renal impairment, and hepatic impairment. All patients were divided equally into three groups by a simple randomization method using computer-generated random numbers i.e.,Group A(Silodosin 4 mg on-demand), Group B (Dapoxetine 30 mg on-demand), and Group C (placebo on demand). Intravaginal ejaculatory latency time (IELT), premature ejaculation profile (PEP), and the clinical global impression of change for premature ejaculation (CGIC) were recorded in patients, before the initiation of the treatment and after ten coital activities or after one month. Any adverse effects reported by the patients were also recorded.
Results: There was a significant improvement in intravaginal ejaculation latency time in both Silodosin and Dapoxetine groups. Patients of group A and group B reported better scores in all aspects of premature ejaculation profile as compared to placebo. Only three patients reported a reduced amount of ejaculate with silodosin but it was not bothersome to patients.
Conclusion: Silodosin 4 mg may be used safely as a treatment option for PME as its safety profile in LUTS is already well established. It is as effective as Dapoxetine 30 mg with a better side effect profile in the management of premature ejaculation.
- Article View: 241
- PDF Download: 421